Erasca Inc. Common Stock (NASDAQ: ERAS)
10 Days left to seek lead plaintiff status.
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material facts, including that: (1) ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc. (“RevMed”) and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.